APA Comments on FDA's First Approval of Medication to Treat Pediatric Schizophrenia and Bipolar Disorder

(August 22, 2007) -- PRNewswire-USNewswire/ -- The American Psychiatric Association (APA) applauds the U.S. Food and Drug Administration (FDA) for its review of scientific evidence that led to the approval of a new treatment for two severe psychiatric disorders in children (schizophrenia and bipolar). The APA is pleased that the approvals are a result of the federal Best Pharmaceuticals for Children Act (BCPA), which was designed to encourage research that leads to this kind of approval, given that dosages, side effects and efficacy can vary significantly with children.

"Schizophrenia and bipolar disorder are severely disabling to patients and devastating to their families," said APA President Carolyn Robinowitz, M.D. "For many children suffering with psychiatric illnesses, medications are an important part of a comprehensive treatment program, which should include talk therapy and other interventions."

"For any medication there are benefits and potential risks," said Darrel Regier, M.D., M.P.H., director, APA Division of Research, and executive director, American Psychiatric Institute for Research and Education. "For many children with these disorders, the FDA's action today provides additional information to guide treatment options in these special populations. We anticipate that approval of this medication will encourage federal research agencies to accelerate urgently needed studies of mental disorders in children."

Physicians and parents must work together to evaluate the risks and benefits of any particular treatment. The APA recommends that all treatment for psychiatric illnesses are guided by a thorough evaluation and careful diagnosis, followed up with a treatment plan tailored to the needs of the child and the family.

About the American Psychiatric Association:

The American Psychiatric Association is a national medical specialty society whose more than 38,000 physician members specialize in diagnosis, treatment, prevention and research of mental illnesses including substance use disorders. Visit the APA at http://www.psych.org and http://www.HealthyMinds.org.

Source: American Psychiatric Association

Last updated: 08/07

Related Information:

• Risperidone (Risperdal) Gets FDA Nod for Schizophrenia and Bipolar Disorder in Kids
• Approval of J&J's Antipsychotic Delayed for Teens
• Symptoms of Child-Onset Schizophrenia
• Symptoms and Diagnosis of Schizophrenia in Children and Young Adults
• Bipolar in Children
• Lithium Builds Gray Matter In Bipolar Brains, UCLA Study Shows Researchers Make Great Leap in Understanding Bipolar Disorder
• Excerpts From Night Falls Fast
• Lithium Carbonate, Eskalith Patient Information
• Researchers Make Great Leap in Understanding Bipolar Disorder
• Internal Body Clock Linked to Mania in Mice
• Record Gift To Fund New Center
• Diagnosing And Treating Bipolar Disorder
• Addictions and Dual Diagnosis - Conference Transcript
• Types of Bipolar Medications: Antidepressants and Antipsychotics
• Effects of Untreated or Undertreated Bipolar Disorder
• Is Bipolar Disorder A Biochemical Problem or Something That's Inherited?
• Researchers Identify Gene Involved in Bipolar Disorder
• Genetics of Bipolar Disorder
• Bipolar Disorder and Schizophrenia Have Similar Genetic Roots
• Bipolar Disorder Often Missed
• The Chemical Fingerprints of Mental Illness
• Finding Bipolar Disorder with MRI
• Just Diagnosed With Bipolar - A Guide
• Symptoms of Bipolar: Mania and Depression
• Early Warning Signs of a Relapse or Oncoming Episode
• Questions to Ask Your Doctor
• How to Manage a Manic Episode
• Bipolar Patients Show Differences in MRI
• Brain Damage From Bipolar Disorder
• Bipolar FAQs - Answers All Your Basic Questions
• Family-Focused Therapy Helps Bipolar Patients Cope

back to top ~ bipolar news index ~ send page to a friend